Skip to main content
Premium Trial:

Request an Annual Quote

Hennessey Elected Director of Repligen

Premium

NEEDHAM, Mass.--Robert Hennessey, chairman, president, and CEO of Genome Therapeutics in Waltham, Mass., has been elected a director of Repligen here. Repligen develops combinatorial chemistry synthesis and high-throughput screening technologies for the accelerated discovery of new drugs capable of blocking certain protein-carbohydrate and protein-protein interactions, for application in cancer and inflammatory disorders. Hennessey joined Genome Therapeutics in 1993 and refocused the company on genomics. He is also a director of PenWest Pharmaceuticals and Virus Research Institute.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.